SAN DIEGO --(BUSINESS WIRE)--Sep. 5, 2023-- Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H.C. Wainwright 25 th Annual Global Investment Conference being held
Company presentation features neuro-oncology program with goal of becoming standard of care for diagnosis, characterization and monitoring of metastatic spread of solid tumors to the central nervous system (CNS) Provides update on COVID-19 testing with more than 300,000 samples received SAN DIEGO
SAN DIEGO --(BUSINESS WIRE)--Jul. 19, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall , President and CEO, will participate at the following investment conferences: Brookline Capital Markets Newport
SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael Nall is scheduled to present a corporate overview at the 2015 Aegis
SAN DIEGO --(BUSINESS WIRE)--Sep. 7, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, announces that Michael Nall , President and CEO, will present at four upcoming investor conferences as follows: H.C. Wainwright 23 rd Annual Global Investment
CEO Michael Nall to participate in diagnostics and devices panel discussion hosted by former FDA Commissioner Dr. Scott Gottlieb SAN DIEGO , Jan. 4, 2021 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to
SAN DIEGO , Nov. 25, 2015 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of patients with cancer, announces that President and CEO Michael Nall is
Biocept to present at Molecular Tri-Conference on Circulating Tumor Cells (CTCs) San Diego, California – Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) in cancer patients, announced that two of its
Presentation to focus on identifying medically actionable biomarkers in cancer patients using liquid biopsy to analyze both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA)
